Amphastar Pharmaceuticals (AMPH) director reports initial insider ownership

Rhea-AI Filing Summary

Amphastar Pharmaceuticals, Inc. identifies Anthony T. Pierce as a director and reporting person in an initial insider ownership report. The disclosure shows no equity or derivative holdings and no buy, sell, exercise, or other transactions reported for him in Amphastar securities.

Filing Explained

The initial director filing reports no beneficial ownership and no disclosed securities transaction affecting Amphastar’s ownership structure.

The July 13 Form 3 is an initial beneficial-ownership statement for a director of Amphastar Pharmaceuticals, tied to an event dated 2026-07-09; it reports no securities beneficially owned, so it discloses no new ownership stake for the filer or issuer-level ownership transaction in this filing.

The filing’s non-derivative and derivative ownership tables contain no reported securities, and its remarks expressly state that no securities are beneficially owned.

Accordingly, this filing records the director relationship and the initial reporting state but does not disclose a securities transaction by the filer.

Key Figures

Reported buy transactions: 0 shares Reported sell transactions: 0 shares Derivative transactions reported: 0

3 metrics

Reported buy transactions 0 shares Initial beneficial ownership statement for Anthony T. Pierce

Reported sell transactions 0 shares Initial beneficial ownership statement for Anthony T. Pierce

Derivative transactions reported 0 Derivative transaction count in Anthony T. Pierce's initial report

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/13/2026 - 07:36 PM Accepted by SEC EDGAR 07/13/2026 - 07:36 PM Learn about SEC filing dates

FAQ

What does Amphastar (AMPH) report about Anthony T. Pierce in this Form 3?

Amphastar Pharmaceuticals reports that Anthony T. Pierce is a director and reporting person in an initial insider ownership statement. The disclosure focuses on his insider status and does not show any reported share or derivative positions or any transactions involving Amphastar securities for him.

Does Anthony T. Pierce report any Amphastar (AMPH) share ownership in this Form 3?

No, the Form 3 shows no reported Amphastar share or derivative holdings for Anthony T. Pierce. All transaction and holding-related counts are zero, indicating no listed equity position or derivative securities associated with him at the time of this initial ownership report.

Are there any insider transactions for Amphastar (AMPH) reported by Anthony T. Pierce?

No, the insider ownership statement reports zero buy, sell, exercise, gift, or tax-withholding transactions for Anthony T. Pierce. Transaction counters, including net buy/sell shares and derivative transaction counts, are all zero in this initial disclosure for Amphastar securities.

Is Anthony T. Pierce a ten percent owner of Amphastar (AMPH)?

No, the structured ownership data indicates Anthony T. Pierce is not a ten percent owner of Amphastar. He is identified as a director and reporting person, but the ten-percent-owner flag is set to zero, reflecting no such ownership status in this report.

What role does Anthony T. Pierce hold at Amphastar (AMPH) according to the Form 3?

Anthony T. Pierce is identified as a director of Amphastar Pharmaceuticals in the insider ownership data. He is not listed as an officer and has no officer title associated with his name in this initial beneficial ownership statement for the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pierce Anthony T

(Last) (First) (Middle)

C/O AMPHASTAR PHARMACEUTICALS, INC.

11570 6TH STREET

(Street)

RANCHO CUCAMONGA CALIFORNIA 91730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/09/2026

3. Issuer Name and Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [ AMPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Eva Wen, by power of attorney	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)